AbCellera Biologics Inc. (ABCL) Institutional Ownership

Ownership Summary

AbCellera Biologics Inc. (NASDAQ:ABCL) is held by 144 institutional investors per 13F filings through December 2025.

• Their combined ownership stood at 36.3% of outstanding shares in December 2025, up from 35.9% in September 2025.
• They increased total shares held in AbCellera Biologics by 17.72% from the prior quarter, while the number of investors in ABCL increased 1.41% year over year.
• Of these 144 funds, 80 grew their exposure to AbCellera Biologics, 38 cut back, and 26 maintained positions.
• Altogether, these fund groups held 108.59Mn shares in ABCL by December 2025, up by 16.35Mn shares quarter on quarter, and down 17.01Mn shares year over year.
• BAKER BROS. ADVISORS LP leads ownership in ABCL with 30.28Mn shares as of December 31, 2025, equal to 10.13% of outstanding shares.
• The biggest buyers of AbCellera Biologics for the quarter ending December 2025 included TD Waterhouse Canada Inc. (9.54Mn), TWO SIGMA INVESTMENTS, LP (4.75Mn), BAKER BROS. ADVISORS LP (2.75Mn), Jefferies Financial Group Inc. (2.75Mn), Alyeska Investment Group, L.P. (2.59Mn).
• Leading sellers of AbCellera Biologics shares for the quarter ending December 2025 were Goldman Sachs Group Inc (4.94Mn), RENAISSANCE TECHNOLOGIES LLC (878.6K), Morgan Stanley (777.02K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (774.17K), JANE STREET GROUP, LLC (549.21K).
• AbCellera Biologics's 10 largest shareholders as of December 2025 include BAKER BROS. ADVISORS LP (30.28Mn), Capital World Investors (13.36Mn), TWO SIGMA INVESTMENTS, LP (10.56Mn), TD Waterhouse Canada Inc. (9.56Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (7.58Mn), UBS Group AG (4.21Mn), ArrowMark Colorado Holdings LLC (4.11Mn), BlackRock, Inc. (4.04Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (4.02Mn), Goldman Sachs Group Inc (3.75Mn) per Business Quant data.